Spliceosomal gene aberrations are rare, coexist with oncogenic mutations, and are unlikely to exert a driver effect in childhood MDS and JMML.
暂无分享,去创建一个
Franco Locatelli | Michael Heuser | Seishi Ogawa | Brigitte Schlegelberger | Michael Dworzak | M. Heuser | F. Thol | S. Ogawa | M. Wlodarski | I. Baumann | C. Niemeyer | T. Klingebiel | F. Locatelli | J. Starý | B. Gruhn | H. Hasle | C. Flotho | B. De Moerloose | B. Schlegelberger | M. Dworzak | M. V. D. van den Heuvel-Eibrink | M. Zecca | B. Strahm | Thomas Klingebiel | Brigitte Strahm | Barbara De Moerloose | Henrik Hasle | Jan Stary | Christian Flotho | Felicitas Thol | Charlotte M Niemeyer | Marcin W Wlodarski | E. Bergstraesser | Shinsuke Hirabayashi | Jessica Moetter | Bernd Gruhn | Irith Baumann | Marco Zecca | Eva Bergstraesser | Marry M van den Heuvel-Eibrink | S. Hirabayashi | Jessica Moetter | Shinsuke Hirabayashi
[1] A. Jankowska,et al. Spectrum of molecular defects in juvenile myelomonocytic leukaemia includes ASXL1 mutations , 2010, British journal of haematology.
[2] S. Sugano,et al. Frequent pathway mutations of splicing machinery in myelodysplasia , 2011, Nature.
[3] I. Baumann,et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases , 2003, Leukemia.
[4] K. Sotlar,et al. KITD816V+ systemic mastocytosis associated with KITD816V+ acute erythroid leukaemia: first case report with molecular evidence for same progenitor cell derivation , 2009, Journal of Clinical Pathology.
[5] O. Abdel-Wahab,et al. The spliceosome as an indicted conspirator in myeloid malignancies. , 2011, Cancer cell.
[6] J. Porter. Oral iron chelators: Prospects for future development , 1989, European journal of haematology.
[7] M. Stratton,et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. , 2011, The New England journal of medicine.
[8] A. Jankowska,et al. Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia. , 2010, Blood.
[9] M. Wlodarski,et al. Abnormal promoter DNA methylation in juvenile myelomonocytic leukemia is not caused by mutation in DNMT3A. , 2011, Blood.
[10] A. Jankowska,et al. SF3B1, a splicing factor is frequently mutated in refractory anemia with ring sideroblasts , 2012, Leukemia.
[11] H. Heimpel,et al. A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes , 2004, Leukemia.
[12] A. Ganser,et al. Immunosuppressive therapy for patients with myelodysplastic syndrome: a prospective randomized multicenter phase III trial comparing antithymocyte globulin plus cyclosporine with best supportive care--SAKK 33/99. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] A. Ganser,et al. Treatment of patients with low-risk myelodysplastic syndromes using a combination of all-trans retinoic acid, interferon alpha, and granulocyte colony-stimulating factor , 1999, Annals of Hematology.
[14] C. Bloomfield,et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.
[15] C. O'keefe,et al. Pathologic clonal cytotoxic T-cell responses: nonrandom nature of the T-cell-receptor restriction in large granular lymphocyte leukemia. , 2005, Blood.
[16] Y. Hayashi,et al. Childhood myelodysplastic syndromes with 11p15 translocation. , 1988, Cancer genetics and cytogenetics.
[17] C. Niemeyer,et al. Advances in the prognostication and management of advanced MDS in children , 2011, British journal of haematology.
[18] K. Bhalla,et al. Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V. , 2009, Leukemia research.
[19] M. Heuser,et al. Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML–BFM and DCOG study groups , 2011, Leukemia.